Program expands access to care supporting the Diagnostics Access Initiative
PLEASANTON, Calif., Sept.
KING OF PRUSSIA, Pa., Sept. 25, 2014 /PRNewswire/ -- Universal Health Services, Inc.
Shire Pharmaceuticals LLC to Pay $56.5 Million to Resolve False Claims Act Allegations Relating to Drug Marketing and Promotion Practices
WHIPPANY, N.J., Sept. 24, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
FDA Submission Reinforces Commitment to Addressing Significant Unmet Needs for Patients With Acute Lymphoblastic Leukemia, an Aggressive Cancer With Limited Treatment Options
Bayer Receives Approval for EYLEA® for the Treatment of Myopic Choroidal Neovascularization in Japan
Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal
Culinary Expert Visits San Diego County on September 20 to Help Educate At-Risk Population About Ingredients for Successful Blood Sugar Management
European Commission Grants Marketing Authorization for Gilead's Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
- Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise
CYRAMZA™ In Combination With Paclitaxel Significantly Improves Overall Survival In Second-Line Gastric Cancer Patients
-- Phase III RAINBOW Trial Data Published in The Lancet Oncology --
INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Eli Lil